We all know that remdesivir has been and will continue to be a life-saving therapeutic for COVID-19 patients. The challenge has been to find ways to make it available and affordable to every patient in the World that needs it. M4ALL’s recently released process addresses one of the key bottlenecks in scaled manufacturing. Congratulations to Frank Gupton and the entire M4ALL team on this important contribution to the global fight against COVID-19.
